Tobias Derfuss

University of Basel - University Hospital Basel

Wilhelm-Klein-Strasse 27

Basel, 4025

Switzerland

SCHOLARLY PAPERS

1

DOWNLOADS

40

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

Efficacy and Safety of Temelimab, an Antibody Antagonist of the Human Endogenous Retrovirus Type-W env Protein, in Participants with Relapsing Remitting Multiple Sclerosis: A Double-Blind, Randomised, Placebo-Controlled Phase 2b Clinical Trial

Number of pages: 130 Posted: 17 May 2019
Heinrich Heine University Dusseldorf - Department of Neurology, University of Basel - University Hospital Basel, University of California, San Francisco (UCSF) - Weill Institute for Neurosciences, Department of Health Sciences (DISSAL), Medical University of Lodz, University College London - Institute of Neurology, University College London - Institute of Neurology, University College London - Institute of Neurology, Servier International Research Institute (IRIS), GeNeuro SA, GeNeuro SA, Servier International Research Institute (IRIS), GeNeuro SA, GeNeuro SA and VU University Amsterdam - Neuroscience Campus Amsterdam
Downloads 40 (502,689)

Abstract:

Loading...

Multiple sclerosis; HERV-directed temelimab; phase 2 trial; neuroprotection